A toxicoproteomic study on cardioprotective effects of pre-administration of docetaxel in a mouse model of adriamycin-induced cardiotoxicity

Biochemical Pharmacology

Volumn 80, Issue 4, 2010, Pages 540-547

  Ohyama, Kaname ^a   Tomonari, Mari ^b   Ichibangase, Tomoko ^c   To, Hideto ^b   Kishikawa, Naoya ^a   Nakashima, Kenichiro ^a   Imai, Kazuhiro ^c   Kuroda, Naotaka ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^c MUSASHINO UNIVERSITY   (Japan)

Author keywords

Adriamycin induced cardiotoxicity; Docetaxel pre administration; Fluorogenic derivatization liquid chromatography tandem mass spectrometry; Toxicoproteomics

Indexed keywords

ACONITATE HYDRATASE; ACONITATE HYDRATASE 2; CREATINE KINASE; DIAZEPAM BINDING INHIBITOR; DOCETAXEL; DOXORUBICIN; ELECTRON TRANSFERRING FLAVOPROTEIN; FRUCTOSE BISPHOSPHATE ALDOLASE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE ISOENZYME; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ISOENZYME 5; SODIUM CHLORIDE; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMICS; CARDIOTOXICITY; CELL ENERGY; CITRIC ACID CYCLE; DERIVATIZATION; DRUG INTERMITTENT THERAPY; DRUG TARGETING; ENERGY METABOLISM; FLUORESCENCE ANALYSIS; GLYCOLYSIS; HEART; HEART PROTECTION; LIQUID CHROMATOGRAPHY; MALE; MITOCHONDRIAL ENERGY TRANSFER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TOXICOPROTEOMICS;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG ANTAGONISM; HEART DISEASES; MALE; MICE; MICE, INBRED ICR; TAXOIDS;

EID: 77953915996     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.04.037     Document Type: Article

References (60)

1. Buzdar A.U., Marcus C., Smith T.L., Blumenschein G.R. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 1985, 55:2761-2765.
2. Bontenbal M., Creemers G.-J., Braun H.J., de Boer A.C., Janssen J.Th, Leys R.B., et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch community setting trial for the clinical trial group of the comprehensive cancer center. J Clin Oncol 2005, 23:7081-7088.
3. Nabholtz J.M., Falkson C., Campos D., Szanto J., Martin M., Chan S., et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003, 21:968-975.
4. Mattioli R., Lippe P., Massacesi C., Cappelletti C., Nacciarriti D., Bisonni R., et al. Long-survival in responding patients with metastatic breast cancer treated with doxorubicin-docetaxel combination. A multicenter phase II trial. Anticancer Res 2004, 24:3257-3262.
5. Lévi F., Zidani R., Misset J. Randomized multicenter trial of chronotherapy with oxaliplatin, fluorouracil, and folic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997, 350:681-686.
6. Kobayashi M., To H., A Tokue A., Fujimura A., Kobayashi E. Cisplatin-induced vomiting depends on circadian timing. Chronobiol Int 2001, 18:851-863.
7. To H., Kikuchi A., Tsuruoka S., Sugimoto K., Fujimura A., Higuchi S., et al. Time-dependent nephrotoxicity associated with daily administration of cisplatin in mice. J Pharm Pharmacol 2000, 52:1499-1504.
8. Hrushesky W.J. Circadian timing of cancer chemotherapy. Science 1985, 228:73-75.
9. Tampellini M., Filipski E., Liu X.H., Lemaigre G., Li X.M., Francois E., et al. Docetaxel chronopharmacology in mice. Cancer Res 1998, 58:3896-3904.
10. To H., Ohdo S., Shin M., Uchimaru H., Yukawa E., Higuchi S., et al. Dosing-time dependency of adriamycin-induced cardiotoxicity and bone marrow toxicity in rats. J Pharm Pharmacol 2003, 55:803-810.
11. Lévi F., Halberg F., Haus E. Synthetic adrenocorticotropin for optimizing murine circadian chronotolerance for adriamycin. Chronobiologia 1980, 7:227-244.
12. Scheving L.E., Burns E.R., Pauly J.E., Halberg F. Circadian bioperiodic response of mice bearing advanced L1210 leukemia to combination therapy with adriamycin and cyclophosphamide. Cancer Res 1980, 40:1511-1515.
13. Barrett R.J., Blessing J.A., Homesley H.D., Twiggs L., Webster K.D. Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma. A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1993, 16:494-496.
14. To H., Shin M., Tabuchi M., Sakaguchi H., Takeuchi A., Matsunaga N., et al. Influence of dosing schedule on toxicity and antitumor effects of a combination of adriamycin and docetaxel in mice. Clin Cancer Res 2004, 10:762-769.
15. Tabuchi M., To H., Sakaguchi H., Goto N., Takeuchi A., Higuchi S., et al. Therapeutic index by combination of adriamycin and docetaxel depends on dosing time in mice. Cancer Res 2005, 65:8448-8454.
16. Sakaguchi H., Kodama A., Tomonari M., Ando Y., Tabuchi M., To H., et al. Pre-administration of docetaxel protects against adriamycin-induced cardiotoxicity. Breast Cancer Res Treat 2008, 109:443-450.
17. Ge Y., Preston R.J., Owen R.D. Toxicoproteomics and its application to human health risk assessment. Proteomics Clin Appl 2007, 1:1613-1624.
18. Bandara L.R., Kennedy S. Toxicoproteomics-a new preclinical tool. Drug Discov Today 2002, 7:411-418.
19. Toriumi C., Imai K. An identification method for altered proteins in tissues utilizing fluorogenic derivatization, liquid chromatography, tandem mass spectrometry, and a database searching algorithm. Anal Chem 2003, 75:3725-3730.
20. Masuda M., Toriumi C., Santa T., Imai K. Fluorogenic derivatization reagents suitable for isolation and identification of cystein-containing proteins utilizing high-performance liquid chromatography-tandem mass spectrometry. Anal Chem 2004, 76:728-735.
21. Masuda M., Saimaru H., Takamura N., Imai K. An improved method for proteomic studies on C. elegans by fluorogenic derivatization, HPLC isolation, enzymatic digestion, and liquid chromatography-tandem mass spectrometric identification. Biomed Chromatogr 2005, 19:556-560.
22. Ichibangase T., Saimaru H., Takamura N., Kuwahara T., Koyama A., Iwatsubo T., et al. Proteomics of Caenorhabditis elegans over-expressing human alpha-synuclein analyzed by fluorogenic derivatization-liquid chromatography/tandem mass spectrometry: identification of Actin and several ribosomal proteins as negative markers at early Parkinson's disease stages. Biomed Chromatogr 2008, 22:232-234.
23. Ichibangase T., Moriya K., Koike K., Imai K. A proteomic method revealing disease-related proteins in livers of hepatitis-infected mouse model. J Proteome Res 2007, 6:2841-2849.
24. Imai K., Ichibangase T., Saitoh R., Horikawa Y. A proteomics study on human breast cancer cell lines by fluorogenic derivatization-liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2008, 22:1304-1314.
25. Asamoto H., Ichibangase T., Uchikuro K., Imai K. Application of an improved proteomics method, fluorogenic derivatization-liquid chromatography-tandem mass spectrometry, to differential analysis of proteins in small regions of mouse brain. J Chromatogr A 2008, 1208:147-155.
26. Ichibangase T., Imai K. Application of fluorogenic derivatization-liquid chromatography-tandem mass spectrometric proteome method to skeletal muscle proteins in fast thoroughbred horses. J Proteome Res 2009, 8:2129-2134.
27. Nozaki N., Shishido T., Takeishi Y., Kubota I. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation 2004, 110:2869-2874.
28. Wu W.W., Wang G., Baek S.J., Shen R.F. Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J Proteome Res 2006, 5:651-658.
29. Qu J., Jusko W.J., Straubinger R.M. Utility of cleavable isotope-coated affinity-tagged reagents for quantification of low-copy proteins induced by methylprednisolone using liquid chromatography/tandem mass spectrometry. Anal Chem 2006, 78:4543-4552.
30. Miseta A., Csutora P. Relationship between the occurrence of cystein in proteins and the complexity of organism. Mol Biol Evol 2000, 17:1232-1239.
31. Welch K.D., Wen B., Goodlett D.R., Yi E., Lee H., Reilly T., et al. Proteomic identification of potential susceptibility factors in drug-induced liver disease. Chem Res Toxicol 2005, 18:924-933.
32. Hirsch J., Hansen K.C., Choi S., Noh J., Hirose R., Roberts J., et al. Warm ischemia-induced alterations in oxidative and inflammatory proteins in hepatic kupffer cells in rats. Mol Cell Protemics 2006, 5:979-986.
33. Turakhia S., Venkatakrishnan C.D., Dunsmore K., Wong H., Kuppusamy P., Zweier J.L., et al. Doxorubicin-induced cardiotoxicity: direct correlation of cardiac fibroblast and H9c2 cell survival and aconitase activity with heat shock protein 27. Am J Physiol Heart Circ Physiol 2007, 293:3111-3121.
34. Sacco G., Giampietro R., Salvatorelli E., Menna P., Bertani N., Graiani G., et al. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity. Br J Pharmacol 2003, 139:641-651.
35. Dzeja P.P., Redfield M.M., Burnett J.C., Terzic A. Failing energetics in failing hearts. Curr Cardiol Rep 2000, 2:212-217.
36. Ingwall J.S., Weiss R.G. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 2004, 95:135-146.
37. Ventura-Clapier R., Garnier A., Veksler V. Energy metabolism in heart failure. J Physiol 2004, 555:1-13.
38. Wallace K.B. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 2003, 93:105-115.
39. Jeyaseelan R., Poizat C., Wu H.Y., Kedes L. Molecular mechanisms of doxorubicin-induced cardiomyopathy. J Biol Chem 1997, 272:5828-5832.
40. Zhou S., Heller L.J., Wallace K.B. Interference with calcium-dependent mitochondrial bioenergetics in cardiac myocytes isolated from doxorubicin-treated rats. Toxicol Appl Pharmacol 2001, 175:60-67.
41. Bruynzeel A., Abou El Hassan M.A., Schalkwijk C., Berkhof J., Bast A., Niessen H.W.M., et al. Anti-inflammatory agents and mono HER protect against DOX-induced cardiotoxicity and accumulation of CML in mice. Br J Cancer 2007, 96:937-943.
42. Riad A., Bien S., Westermann D., Becher P.M., Loya K., Landmesser U., et al. Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice. Cancer Res 2009, 69:695-699.
43. Eidenschink A.B., Schroter G., Muller-Weihrich S., Stern H. Myocardial high-energy phosphate metabolism is altered after treatment with anthracycline in childhood. Cardiol Young 2000, 10:610-617.
44. Tokarska-Schlattner M., Zaugg M., Zuppinger C., Wallimann T., Schlattner U. New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics. J Mol Cell Cardiol 2006, 41:389-405.
45. Phadke M.S., Krynetskaia N.F., Mishra A.K., Krynetskiy E. Glyceraldehyde 3-phosphate dehydrogenase depletion induces cell cycle arrest and resistance to antimetabolites in human carcinoma cell lines. J Pharmacol Exp Ther 2009, 331:77-86.
46. Shinohara M.L., Loros J.J., Dunlap J.C. Glyceraldehyde-3-phosphate dehydrogenase is regulated on a daily basis by the circadian clock. J Biol Chem 1998, 273:446-452.
47. Beisswenger P.J., Howell S.K., Smith K., Szwergold B.S. Glyceraldehyde-3-phosphate dehydrogenase activity as an independent modifier of methylglyoxal levels in diabetes. Biochim Biophys Acta Mol Basis Dis 2003, 1637:98-106.
48. Wolf M.B., Baynes J.W. The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim Biophys Acta 2006, 1760:267-271.
49. Baek D., Jin Y., Jeong J.C., Lee H.J., Moon H., Lee J., et al. Suppression of reactive oxygen species by glyceraldehyde-3-phosphate dehydrogenase. Phytochemstry 2008, 69:333-338.
50. Kawai-Yamada M., Jin L., Yoshinaga K., Hirata A., Uchimiya H. Mammalian Bax inhibitor-1 suppressing Bax-, hydrogen peroxide-, and salicylic acid-induced cell death. Plant Cell 2004, 16:21-32.
51. Sirover M.A. New nuclear functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells. J Cell Biochem 2005, 95:45-52.
52. Colell A., Ricci J.E., Tait S., Milasta S., Maurer U., Bouchier-Hayes L., et al. GAPDH and autophagy preserve survival after apoptoic cytochrome c release in the absence of caspase activation. Cell 2007, 129:983-997.
53. Zhang L., Roeder R.G., Luo Y. S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell 2003, 114:255-266.
54. Hara M.R., Agrawal N., Kim S.F., Cascio M.B., Fujimuro M., Ozeki Y., et al. S-nitrosylated GAPDH initiates apoptoic cell death by nuclear translocation following Siah1 binding. Nat Cell Biol 2005, 7:665-674.
55. Hara M.R., Thomas B., Cascio M.B., Bae B.I., Hester L.D., Dawson V.L., et al. Neuroprotection by pharmacologic blockage of the GAPDH death cascade. Proc Natl Acad Sci USA 2006, 103:3887-3889.
56. Chen Y., Daosukho C., Opii W.O., Turner D.M., Pierce W.M., Klein J.B., et al. Redox proteomic identification of oxidized cardiac proteins in adriamycin-treated mice. Free Radic Biol Med 2006, 41:1470-1477.
57. Merten K.E., Feng W., Zhang L., Pierce W., Cai J., Klein J.B., et al. Modulation of cytochrome c oxidase-Va is possibly involved in metallothionein protection from doxorubicin cardiotoxicity. J Pharmacol Exp Ther 2005, 315:1314-1319.
58. Yen H.C., Oberley T.D., Vichitbandha S., Ho Y.S., Clair DKSt. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 1996, 98:1253-1260.
59. Kang Y.J., Sun X.H., Chen Y., Zhou Z.X. Inhibition of doxorubicin chronic toxicity in catalase-overexpressing transgenic mouse heart. Chem Res Toxicol 2002, 15:1-6.
60. + analogue is a nanomolar inhibitor of trypanosomal glyceraldehyde-3-phosphate dehydrogenase. Bioorg Med Chem Lett 2001, 11:95-98.